menu
    • menu
    [{"orgOrder":0,"company":"RadioMedix","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Agreement","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"RadioMedix \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"RadioMedix \/ Plus Therapeutics"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Oranomed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"212-Pb Dotamtate","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RadioMedix \/ Oranomed","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Oranomed"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Portland Investment Counsel Inc.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Series A Financing","leadProduct":"212-Pb Dotamtate","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RadioMedix \/ Portland Investment Counsel Inc.","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Portland Investment Counsel Inc."},{"orgOrder":0,"company":"RadioMedix","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Acquisition","leadProduct":"225-Ac PSMA","moa":"Alpha-wave","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RadioMedix \/ Fusion Pharma","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Fusion Pharma"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Oranomed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"212-Pb Dotamtate","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RadioMedix \/ Oranomed","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Oranomed"}]

    Find Clinical Drug Pipeline Developments & Deals by RadioMedix

    Menu

    RadioMedix

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            RadioMedix

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            RadioMedix

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 212-Pb Dotamtate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Oranomed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RadioMedix and Orano Med Receive Breakthrough Designation for AlphaMedixTM

                            Details : AlphaMedix (212Pb-DOTAMTATE) is a targeted alpha therapy for unresectable, metastatic gastroenteropancreatic neuroendocrine tumors, naïve to peptide receptor therapy.

                            Product Name : Alphamedix

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            December 02, 2024

                            Lead Product(s) : 212-Pb Dotamtate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Oranomed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            RadioMedix

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            RadioMedix

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 212-Pb Dotamtate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Oranomed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in ...

                            Details : AlphaMedixTM is a radiolabeled SSTR-targeting therapeutic investigational drug for the treatment of NETs patients. The product consists of SSTR-targeting peptide complex radiolabeled with 212Pb dotamtate that serves as an in vivo generator of alpha-emitt...

                            Product Name : Alphamedix

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            May 16, 2023

                            Lead Product(s) : 212-Pb Dotamtate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Oranomed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            RadioMedix

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            RadioMedix

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 225-Ac PSMA

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Fusion Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            RadioMedix Inc. Announces the Acquisition of its 225Ac-PSMA I&T program, a Targeted Alpha Therapy (TAT) for Me...

                            Details : Through the acquisition of Phase 2 program evaluating 225Ac-PSMA I&T, a small molecule targeting prostate specific membrane antigen ("PSMA") expressed on prostate cancers, strengthens the pipeline of innovative targeted alpha therapies.

                            Product Name : Ac225-PSMA

                            Product Type : Radiolabelled Compounds

                            Upfront Cash : Undisclosed

                            February 15, 2023

                            Lead Product(s) : 225-Ac PSMA

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Fusion Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            RadioMedix

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            RadioMedix

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 212-Pb Dotamtate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Portland Investment Counsel Inc.

                            Deal Size : $40.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            RadioMedix Announces a $40 Million Series A Financing for The Advancement of Novel Targeted Alpha Therapy Plat...

                            Details : The proceeds of the financing will be applied to developing RadioMedix’s flagship radiopharmaceutical AlphaMedix™, a lead-212 (Pb212) labelled somatostatin analogue TAT agent for the treatment of metastatic or inoperable somatostatin expressing neuro...

                            Product Name : Alphamedix

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            July 10, 2022

                            Lead Product(s) : 212-Pb Dotamtate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Portland Investment Counsel Inc.

                            Deal Size : $40.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            RadioMedix

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            RadioMedix

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 186-Re Obisbemeda

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Plus Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Plus Therapeutics Announces Commercial Manufacturing Supply Agreement for Its Lead Investigational Drug

                            Details : This strategic partnership substantially supports efforts to have fully compliant 186RNL available by mid-2022 for a potential Phase 2/3 clinical study in adults with recurrent glioblastoma (GBM).

                            Product Name : 186RNL

                            Product Type : Radiolabelled Compounds

                            Upfront Cash : Undisclosed

                            February 09, 2021

                            Lead Product(s) : 186-Re Obisbemeda

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Plus Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth